Long-term survival of patients with connective tissue disease-associated pulmonary arterial hypertension: A single-center cohort

Pulmonary arterial hypertension (PAH) is a rare but severe complication of connective tissue disease (CTD). CTDassociated PAH (CTD-PAH) is the most common subgroup of PAH in East Asia. We prospectively collected 41 patientswith CTD-PAH and followed them for a mean period of 43 _ 36 months. The long-term survival rates of the CTD-PAH patients at 1, 2, 3 and 5 years were 90%, 80%, 77%, and 60%, respectively. The non-survivors had more dilated main pulmonary arteries, higher pulmonary artery pressure and pulmonary vascular resistance (PVR). PAH-specific therapy resulted in improvements in functional class, 6-minute walk distance, serum uric acid, right ventricular function and PVR. Increased C-reactive protein during follow-up, indicating inflammatory processes, was also crucial for the management of CTD-PAH. Therefore targeting both PAH and inflammation is important in this specific subgroup of PAH. The results of this study may help develop treatment strategies for CTD-PAH patients.